Encorafenib and Binimetinib Combination Treatment Demonstrates 33.6 Month Median Overall Survival (OS) in Patients with BRAF-Mutant Melanoma in Phase 3 COLUMBUS Trial
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/23/2026
- Wall Street futures edge lower after AI selloff, telecom slide
- Meta's capital-raising plans expose a major weakness in the AI boom
- Brent crude hits more than five-month high on concern over Middle East escalation
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
| Array Biopharma, Inc. (NASDAQ: ARRY) | Delayed: 3.30 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $3.30 | 52 Week High | $7.27 | |||
| Open | $3.30 | 52 Week Low | $2.39 | |||
| Day High | $3.30 | P/E | N/A | |||
| Day Low | $3.30 | EPS | $-0.61 | |||
| Volume | 5,450 | |||||
